Tanya Siddiqi, M.D.

888-333-HOPE (4673)
Tanya Siddiqi
Play
Hematologist
4.9 (272 RATINGS)
Clinical Expertise
Hematopoietic Cell Transplantation
Leukemia
Lymphoma
Appointments
Director, Chronic Lymphocytic Leukemia Program, Toni Stephenson Lymphoma Center
Associate Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation
Clinical Teams
Leukemia
Lymphoma
Hematology & Hematopoietic Cell Transplantation
Tanya Siddiqi, M.D., is an accomplished hematologist-oncologist who specializes in diagnosing and treating blood cancers, particularly Chronic Lymphocytic Leukemia (CLL) and B-cell Non-Hodgkin Lymphoma (B-NHL). She is also a supervising physician at City of Hope's anti-coagulation clinic, which treats patient with blood clotting disorders due to their diseases or treatments.
 
In addition to her clinical practice, Dr. Siddiqi is also principal investigator on a number of clinical trials evaluating the role of targeted therapies, including gene therapy (CAR T cell therapy), and other novel agents primarily in diseases like CLL and B-NHL.
 
Dr. Siddiqi earned her medical degree at Aga Khan University Medical College in Karachi, Pakistan. Afterward, she completed an internal medicine residency at University of Connecticut Health Center, followed by fellowships in hematology/oncology at Beth Israel Deaconess Medical Center (Harvard Medical School, Boston) and hematopoietic stem cell transplantation at City of Hope.
 
Dr. Siddiqi is a member of the Immunotherapy Disease Team, Toni Stephenson Lymphoma Center, and the Gehr Family Center for Leukemia Research.
Location
Education & Experience
Degrees

  • 2000 - Aga Khan University Medical College, Karachi, Pakisatan (M.B., B.S.)

Fellowship

  • 2009 - 2010, Fellowship in hematopoietic cell transplantation, City of Hope, Duarte, CA

  • 2006 - 2009, Fellowship in hematology/oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

Residency

  • 2003 - 2006, Internship and residency in internal medicine, University of Connecticut Health Center, Farmington, CT

Professional Experience

  • 2019 - present, Director, Chronic Lymphocytic Leukemia Program, Toni Stephenson Lymphoma Center

  • 2018 - present - Associate Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

  • 2010 - 2018, Assistant clinical professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

  • 2013 - present, Supervising physician, Outpatient Anticoagulation Clinic, City of Hope, Duarte, CA

  • 2009 - 2010, Instructor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

Awards & Memberships
Awards

  • 2016 - Best Lymphoma abstract award, Lymphoma and Myeloma 2016, New York, NY October 13-15, 2016

  • 2016 - Pasadena Magazine Top Doctor, August 2016

  • 2012 - Phase 1 Program Correlative Science Award, City of Hope

  • 2009 - Tim Nesvig Lymphoma Foundation grant

  • 2008 - American Association for Cancer Research Molecular Biology in Clinical Oncology Workshop award

Memberships

  • American Society of Blood and Marrow Transplantation

  • American Society of Clinical Oncology

  • American Society of Hematology

  • Member, NCCN VTD Panel

  • Member, NCCN, CLL\NHL Panel

Publications
  • Dimopoulos M, Sanz RG, Lee HP, Trneny M, Varettoni M, Opat S, D'Sa S, Owen RG, Cull G, Mulligan S, Czyz J, Castillo JJ, Motta M, Siddiqi T, Gironella Mesa M, Granell Gorrochategui M, Talaulikar D, Zinzani PL, Askari E, Grosicki S, Oriol A, Rule S, Kloczko J, Tedeschi A, Buske C, Leblond V, Trotman J, Chan WY, Michel J, Schneider J, Tan Z, Cohen A, Huang J, Tam CS. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. Blood Adv. 2020 Dec 8;4(23):6009-6018. doi: 10.1182/bloodadvances.2020003010. PubMed PMID:33284944; PubMed Central PMCID:PMC7724905
  • Tam CS, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Garcia-Sanz R, McCarthy H, Mulligan S, Tedeschi A, Castillo J, Czyz J, Fernández de Larrea C, Belada D, Libby E, Matous JV, Motta M, Siddiqi T, Tani M, Trneny M, Minnema MC, Buske C, Leblond V, Chan WY, Schneider JY, Ro S, Cohen A, Huang J, Dimopoulos MA. A randomized phase 3 trial of zanubrutinib versus ibrutinib in symptomatic Waldenström Macroglobulinemia: the Aspen study. Blood. 2020 Jul 30:blood.2020006844. doi: 10.1182/blood.2020006844. Online ahead of print. PMID: 32731259
  • Siddiqi T, Frankel P, Ruel C, Beumer JH, Song JY, Scuto A, Chen R, Kelly KR, Popplewell L, Puverel S, Thomas S, Forman SJ, Piekarz R, Newman E. Phase 1 study of the aurora kinase A inhibitor alisertib (MLN8237) in combination with the histone deacetylase inhibitor vorinostat in lymphoid malignancies. Leuk Lymphoma. 2020 Feb;61(2):309-317. doi: 10.1080/10428194.2019.1672052. Epub 2019 Oct 16. PMID: 31617432
  • Lunning M, Vose J, Nastoupil L, Fowler N, Burger JA, Wierda WG, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Sportelli P, Miskin HP, Weiss MS, O'Brien S. Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2019 Nov 21;134(21):1811-1820. doi: 10.1182/blood.2019002118. PMID: 31558467
  • Nastoupil LJ, Lunning MA, Vose JM, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Burger JA, Wierda WG, O'Brien S, Sportelli P, Miskin HP, Purdom MA, Weiss MS, Fowler NH. Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematol. 2019 Feb;6(2):e100-e109. doi: 10.1016/S2352-3026(18)30216-3. PMID: 30709431
  • Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2. PMID: 30518502
  • Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, Gladstone DE, le Coutre P, Dietrich S, Gotic M, Larratt L, Offner F, Schiller G, Swords R, Bacon L, Bocchia M, Bouabdallah K, Breems DA, Cortelezzi A, Dinner S, Doubek M, Gjertsen BT, Gobbi M, Hellmann A, Lepretre S, Maloisel F, Ravandi F, Rousselot P, Rummel M, Siddiqi T, Tadmor T, Troussard X, Yi CA, Saglio G, Roboz GJ, Balic K, Standifer N, He P, Marshall S, Wilson W, Pastan I, Yao NS, Giles F. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 2018 Aug;32(8):1768-1777. doi: 10.1038/s41375-018-0210-1. Epub 2018 Jul 20. PMID: 30030507
  • Chen RW, Palmer JM, Tomassetti S, Popplewell LL, Alluin J, Chomchan P, Nademanee AP, Siddiqi T, Tsai NC, Chen L, Zuo F, Abary R, Cai JL, Herrera AF, Rossi JJ, Rosen ST, Forman SJ, Kwak LW, Holmberg LA. Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. J Hematol Oncol. 2018 Jun 28;11(1):87. doi: 10.1186/s13045-018-0631-3. PMID: 29954415
  • Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10. PMID: 29226797
  • Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, Jiyang Y, Xue AX, Elias M, Aycock J, Wiezorek J, Go W. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Molecular The
  • Siddiqi T, Frankel P, Ruel C, Beumer JH, Song JY, Scuto A, Chen R, Kelly KR, Tuscano J, Popplewell L, Puverel S, Thomas S, Forman SJ, Piekarz R, Newman E. Phase 1 study of Aurora kinase A inhibitor alisertib (MLN8237) and histone deacetylase inhibitor vorinostat in lymphoid malignancies. Manuscript in preparation.
  • Khan M, Siddiqi R, Siddiqi T. The role of prognostic markers in the era of targeted therapy for chronic lymphocytic leukemia. Editorial submitted.
  • Herrera AF, Rodig SJ, Song JY, Kim Y, Griffin GK, Yang D, Nikolaenko L, Mei M, Bedell V, Cin PD, Pak C, Alyea EP, Budde E, Chen R, Chen YB, Chan WC, Cutler CS, Ho VT, Koreth J, Krishnan A, Murata-Collins JL, Nikiforow S, Palmer J, Pihan GA, Pillai R, Popplewell L, Rosen ST, Siddiqi T, Sohani AR, Zain J, Kwak LW, Weisenburger DD, Weinstock DM, Soiffer RJ, Antin JH, Forman SJ, Nademanee AP, Armand P. “Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma”. Biol Blood Marrow Transplant. 2017 Nov 28. pii: S1083-8791(17)30870-4. DOI: 10.1016/j.bbmt.2017.11.023. [Epub ahead of print] PMID: 29196080
  • Mei MG, Cao TM, Chen L, Song J, Siddiqi T, Cai JL, Farol LT, Al Malki MM, Salhotra A, Aldoss I, Palmer J, Herrera AF, Zain J, Popplewell LL, Chen RW, Rosen ST, Forman SJ, Kwak L, Nademanee AP, Budde LE. Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. Biol Blood Marrow Transplant. 2017 Jul 18. pii: S1083-8791(17)30575-X. DOI: 10.1016/j.bbmt.2017.07.006. [Epub ahead of print]
  • Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, Jiyang Y, Xue AX, Elias M, Aycock J, Wiezorek J, Go W. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Molecular Therapy 2017 Jan; 25(1):285-295
  • Bartlett NL, Smith MR, Siddiqi T, Advani RH, O'Connor OA, Sharman JP, Feldman T, Savage KJ, Shustov AR, Diefenbach CS, Oki Y, Palanca-Wessels MC, Uttarwar M, Li M, Yang J, Jacobsen ED. Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. Leuk Lymphoma. 2017 Jul;58(7):1607-1616. doi: 10.1080/10428194.2016.1256481. Epub 2016 Nov 20.
  • Herrera AF, Mei M, Low L, Kim HT, Griffin GK, Song JY, Merryman RW, Bedell V, Pak C, Sun H, Paris T, Stiller T, Brown JR, Budde LE, Chan WC, Chen R, Davids MS, Freedman AS, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, Murata-Collins J, Nademanee AP, Palmer JM, Pihan GA, Pillai R, Popplewell L, Siddiqi T, Sohail AR, Zain J, Rosen ST, Kwak LW, Weinstock DM, Forman SJ, Weisenburger DD, Kim Y, Rodig SJ, Krishnan A, Armand P. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol 2017 Jan; 35: 24-31. Epub 2016 Oct 24. PMID: 28034071
  • O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Österborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016 Oct;17(10):1409-1418. DOI: 10.1016/S1470-2045(16)30212-1. Epub 2016 Sep 13. PMID: 27637985
  • Wang X, Popplewell LL, Wagner JR, Naranjo A, Blanchard MS, Mott MR, Norris AP, Wong CW, Urak RZ, Chang WC, Khaled SK, Siddiqi T, Budde LE, Xu J, Chang B, Gidwaney N, Thomas SH, Cooper LJ, Riddell SR, Brown CE, Jensen MC, Forman SJ. “Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.” Blood. 2016 Jun 16;127(24):2980-90. DOI: 10.1182/blood-2015-12-686725. Epub 2016 Apr 26. PMID: 27118452
  • Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaidano G, Maslyak Z, Stevens DA, Janssens A, Offner F, Mayer J, O'Dwyer M, Hellmann A, Schuh A, Siddiqi T, Polliack A, Tam CS, Suri D, Cheng M, Clow F, Styles L, James DF, Kipps TJ; RESONATE-2 Investigators. “Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.” N Engl J Med. 2015 Dec 17;373(25):2425-37. DOI: 10.1056/NEJMoa1509388. Epub 2015 Dec 6. PMID: 26639149
  • Song JY, Venkatarama G, Fedoriw Y, Herrera AF, Siddiqi T, Alikhan MB, Kim YS, Murata-Collins J, Weisenburger DD, Liu X, Duffield AS. “Burkitt leukemia limited to the bone marrow has a better prognosis than Burkitt lymphoma with bone marrow involvement in adults.” Leuk Lymphoma 2015; 1-6 [epub ahead of print]. PMID: 26450341
  • Streiff MB, Holmstrom B, Ashrani A, Bockenstedt PL, Chesney C, Eby C, Fanikos J, Fenninger RB, Fogerty AE, Gao S, Goldhaber SZ, Hendrie P, Kuderer N, Lee JT, Lovrincevic M, Millenson MM, Neff AT, Ortel TL, Paschal R, Shattil S, Siddiqi T, Smock KJ, Soff G, Wang TF, Yee GC, Zakarija A, McMillian N, Engh AM. “Cancer-associated Venous thromboembolic disease, version 1.2015.” J Natl Compr Canc Netw 2015; 13 (9): 1079-95. PMID: 26358792
  • Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT, Popplewell L, Siddiqi T, Thomas SH, Mott M, Sahebi F, Armenian S, Leonard J, Nademanee A, Forman SJ. “Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.” Biol Blood Marrow Transplant. 2015 Dec;21(12):2136-40. DOI: 10.1016/j.bbmt.2015.07.018. Epub 2015 Jul 26. PMID: 26211987
  • Bachanova V, Burns LJ, Ahn KW, Laport GG, Akpek G, Kharfan-Dabaja MA, Nishihori T, Agura E, Armand P, Jaglowski SM, Cairo MS, Cahsen AF, Cohen JB, D’Souza A, Freytes CO, Gale RP, Ganguly S, Ghosh N, Holmberg LA, Inwards DJ, Kanate AS, Lazarus HM, Malone AK, Munker R, Mussetti A, Norkin M, Prestidge TD, Rowe JM, Satwani P, Siddiqi T, Stiff PJ, William BM, Wirk B, Maloney DG, Smith SM, Sureda AM, Carreras J, Hamdani M; Center for International Blood and Marrow Transplant Research Lymphoma Working Committee. “Impact of pretransplantation (18)F-fluorodeoxy glucose-positron emission tomography status on outcomes after allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.” Biol Blood Marrow Transplant 2015; 21: 1605-11. DOI: 10.1016/j.bbmt.2015.05.007. Epub 2015 May 14. PMID: 25983043
  • Siddiqi T, Rosen ST. “Novel Biologic Agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia – Part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation.” Oncology (Williston Park) 2015; 29: 299-308. Review. PMID: 25920929
  • Siddiqi T, Rosen ST. “Novel Biologic Agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia – Part 1.” Oncology (Williston Park) 2015; 29: 198-203. Review. PMID: 25772456
  • Chen R, Frankel P, Popplewell L, Siddiqi T, Ruel N, Rotter A, Thomas SH, Mott M, Nathwani N, Htut M, Nademanee A, Forman SJ, Kirschbaum M. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. Haematologica. 2015 Mar;100(3):357-62. DOI: 10.3324/haematol.2014.117473. PMID: 25596263
  • Chen R, Palmer JM, Tsai NC, Thomas SH, Siddiqi T, Popplewell L, Farol L, Nademanee A, Forman SJ. “Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma.” Biol Blood Marrow Transplant 2014; 20: 1864-8. PMID: 25008328
  • Siddiqi T, Thomas SH, Chen R. “Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma.” Pharmacogenomics Pers Med 2014 Feb 20; 7: 79-85. PMID: 24672256
  • Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O’Connor OA, Siddiqi T, Kennedy DA, Oki Y. “Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.” Blood 2014 May 15; 123 (20): 3095-100. PMID: 24652992
  • Streiff MB, Bockenstedt PL, Cataland SR, Chesney C, Eby C, Fanikos J, Fogerty AE, Gao S, Goldhaber SZ, Hassoun H, Hendrie P, Holmstrom B, Kuderer N, Lee JT, Millenson MM, Neff AT, Ortel TL, Siddiqi T, Smith JL, Yee GC, Zakarija A, McMillian N, Naganuma M. “Venous thromboembolic disease.” J Natl Compr Canc Netw 2013 Nov; 11 (11): 1402-29. PMID: 24225973
  • Siddiqi T, Blaise D. “Does antithymocyte globulin have a place in reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation?” Hematology Am Soc Hematol Educ Program 2012: 246-50. PMID: 23233588
  • Will B, Siddiqi T (co-1st author), Jorda MA, Shimamura T, Luptakova K, Staber PB, Costa DB, Steidl U, Tenen DG, Kobyashi S. “Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.” Blood 2010 Apr 8; 115 (14): 2901-9. PMID: 20160166
  • Melicoff E, Sansores-Garcia L, Gomez A, Moreira DC, Datta P, Thakur P, Siddiqi T, Murthy J, Dickey BF, Heidelberger R, Adachi R. “Synaptotagmin-2 controls regulated exocytosis but not other secretory responses of mast cells.” J Biol Chem 2009 Jul 17; 284 (29): 19445-51. PMID: 19473977
  • Siddiqi T, Joyce RM. A case of HIV negative primary effusion lymphoma treated with bortezomib, liposomal doxorubicin and rituximab. Clin Lymphoma Myeloma 2008 Oct; 8 (5): 300-4. PMID: 18854285
  • Siddiqi T, Bauer KA, Barbieri RL. Contraception for women with inherited thrombophilias. Up To Date online, 2008 Oct.; updated each year.
  • Abbas F, Memon  A, Siddiqui T, Kayani N, Ahmad  NA. “Granular cell tumors of the urinary bladder.” World J Surg Oncol, 2007 Mar 13; 5:33. PMID: 17355632
  • Ikram M, Khan MA, Ahmed M, Siddiqui T, Mian MY. “The histopathology of routine tonsillectomy specimens: results of a study and review of literature.” Ear Nose Throat J. 2000 Nov; 79 (11): 880-2. PMID: 11107690
  • Ahmed M, Khan AA, Siddiqi T, Ikram M, Mian MY. “A Comparison of Dissection-method and Diathermy Tonsillectomies.” J Pak Med Assoc. 2000 Jul; 50 (7): 215-6. PMID: 10992695
  • Siddiqui T, Pervez S. “Spectrum of Hodgkin’s disease in children and adults: impact of combined morphologic and phenotypic approach for exclusion of ‘look-alikes’.” J Pak Med Assoc. 1999 Sep; 49 (9): 211-4. PMID: 10646321

    
Chapters:

  • Afkhami M, Siddiqi T, Rosen S. “Case study section: Lymphoplasmacytic lymphoma in the era of next generation sequencing.” Lymphoma handbook 2017: A case-based approach. Editors: Zain J, Kwak L. Publisher: Springer
  • Siddiqi T, Rosen ST. “B-SLL and CLL.” Lymphoma handbook 2017: A case-based approach. Editors: Zain J, Kwak L. Publisher: Springer
Ratings & Reviews
Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with 5 stars being the highest.
Ratings
5.0
Show respect for what you say
4.9
Know important info medical history
4.9
Spend enough time with you
4.9
Rate provider 0-10
4.9
Recommend this provider office
4.9
Provider explain in way you understand
4.9
Provider listen carefully to you
Reviews
12/07/22
Dr Siddiqi is very knowledgeable in the type of lymphoma I have. - Verified patient
12/06/22
Everything about this visit was exceptionally good - Verified patient
12/06/22
EVERY Staff member from beginning to end were amazing. Everyone went above and beyond,and we are truly grateful for that!! - Verified patient
11/29/22
After talking with the provider on the phone a couple of times, I really enjoyed meeting in person. - Verified patient
10/29/22
Excellent - Verified patient